Invitae Corp (NVTAQ)

[chmcnfunds]

Thankfully it is. Held through the earning which I usually don't so missed some trading opportunities especially since it is in a Etrade account that doesn't allow pre- and post hours trading. Good luck.

Bullish Fool article from a couple of days ago:

_________________________________________________

3 Top Small-Cap Stocks to Buy in February

Motley Fool

Maxx Chatsko, The Motley Fool
Motley FoolFebruary 23, 2018

The American stock market -- alongside many of its international peers -- has been on fire in recent years, with the S&P 500 delivering total returns of nearly 22% in 2017. Of course, there were some signs that the market was a little overheated and overdue for at least a brief cooldown. That's exactly what investors are witnessing in February.

The sharp volatility in early 2018 is a stunning departure from last year, which was unusual for its lack of major movements -- up or down. But for long-term investors, there's not a whole lot to worry about. The recent pullback could even be a great time to dust off your watchlist in search of buying opportunities. I think genetic testing leader Invitae (NYSE: NVTA), enzyme designer Codexis (NASDAQ: CDXS), and urban cement powerhouse U.S. Concrete (NASDAQ: USCR) are among the top small-cap stocks to buy this month.

Growth compensating for dilution
Invitae has taken the genetic testing market, which helps clinicians and patients identify health risks or pinpoint disease diagnoses, by storm. Rather than selling ultra-expensive tests in low volumes, the company's business model relies on selling affordable tests in large volumes. Essentially, the goal is to greatly expand the market by making genetic testing accessible to just about any individual -- and it's worked so far, with some caveats.

In early January, the company provided investors with preliminary full-year 2017 results and preliminary full-year 2018 guidance. The stock promptly sank nearly 14%. Why? Wall Street was expecting more optimistic guidance for the year ahead. Analysts actually had good reason to be upset. But the stock was punished once again when earnings were finalized, despite the numbers actually being slightly better than the preliminary announcement.

The company achieved year-over-year revenue growth of 172%, but Invitae has been growing so quickly that that's considered a disappointment. The real dismay was prompted by preliminary guidance for the current year. While management forecasts at least $120 million in total revenue, or growth of 79% from 2017, Wall Street was expecting considerably higher sales in 2018 given two recent acquisitions.

However, individual investors don't have to follow Wall Street's lead and pretend that they aren't impressed with the incredible growth being delivered. Even better for long-term investors: With an astounding 30% drop thus far in 2018, Invitae could be a buy right now.

Still, it's not all lollipops and rainbows for the loss-accruing, high-growth company. For instance, there's a very long way to go before the business is profitable. Additionally, management relied on heavy dilution to fuel growth in recent years, which really sapped returns. But even after accounting for that, the company's market cap is now under $340 million for the first time since late 2016 -- a year in which the business coughed up $25 million in revenue. Compare that to at least $120 million expected in the year ahead on considerable growth in testing volume sales, product offerings, and collaborations with biopharma companies and, well, the stock is a comparative bargain given its high-growth credentials.

If you're looking for a hyper-growth stock gobbling up market share in a futuristic industry, then look no further than Invitae. Just be ready for higher-than-average volatility.
_________________________________________
https://finance.yahoo.com/news/3-top-small-cap-stocks-125600815.html

NVTA